GlassScriptPhysician profile
Rabiul Alam
NPI 1841266996
$7,452.97
in general payments reported to CMS, 2019-2025
38 companies · $902 in 2025
The $902 reported for 2025 was more than what 77% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $1,103 · 2021: $3,651 · 2022: $256 · 2023: $84.25 · 2024: $500 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469 · Education: $16.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.96 |
| Education | $16.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $1,442.69 | 2021-2022 | |
| Viiv Healthcare Company | $977.44 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $630.52 | 2019-2025 | |
| Octapharma USA, INC. | $490.06 | 2020-2025 | Panzyga |
| Merck Sharp & Dohme LLC | $447.00 | 2019-2025 | Zerbaxa, Pifeltro, Delstrigo |
| Abbvie INC. | $322.23 | 2019-2025 | |
| Insmed, INC. | $306.77 | 2019-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $300.53 | 2019-2021 | |
| Astellas Pharma US INC | $241.34 | 2019-2025 | Cresemba |
| Melinta Therapeutics, LLC | $239.28 | 2019-2024 | Rezzayo, Orbactiv, Kimyrsa |
| Allergan, INC. | $235.15 | 2019-2020 | |
| Janssen Biotech, INC. | $187.28 | 2019-2021 | |
| Amgen INC. | $186.64 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $183.15 | 2021-2025 | Zevtera |
| Takeda Pharmaceuticals U.S.A., INC. | $165.57 | 2020-2025 | Cuvitru |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $142.79 | 2019-2021 | |
| Pfizer INC. | $140.67 | 2019-2025 | |
| Shionogi INC | $78.39 | 2021-2025 | Fetroja |
| Mayne Pharma Commercial LLC | $73.86 | 2020-2021 | |
| Grifols USA, LLC | $72.45 | 2020-2025 | Xembify |
| Theratechnologies INC. | $70.75 | 2019-2025 | Trogarzo, Egrifta |
| Astrazeneca Pharmaceuticals LP | $58.76 | 2019-2021 | |
| Global Blood Therapeutics, INC. | $53.78 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $50.33 | 2019-2025 | |
| Organogenesis INC. | $49.82 | 2025 | Affinity |
| Kerecis Limited | $41.04 | 2019-2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Napo Pharmaceuticals INC | $33.64 | 2019-2025 | Mytesi |
| Smith+Nephew, INC. | $29.27 | 2021 | |
| Nabriva Therapeutics, Plc | $28.27 | 2020-2021 | |
| Lundbeck LLC | $24.02 | 2020 | |
| Invivyd INC | $23.44 | 2025 | Pemgarda |
| Horizon Therapeutics Plc | $22.87 | 2021 | |
| Csl Behring | $22.86 | 2021 | |
| Tersera Therapeutics LLC | $20.46 | 2024 | Quzyttir |
| Electromed, INC. | $16.01 | 2024 | Smartvest |
| Sanofi Pasteur INC. | $15.55 | 2020 | |
| Mylan Institutional INC. | $14.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabiul Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.